Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment
Macha, S., Mattheus, M., Halabi, A., Pinnetti, S., Woerle, H. J., Broedl, U. C.Volume:
16
Language:
english
Journal:
Diabetes, Obesity and Metabolism
DOI:
10.1111/dom.12182
Date:
March, 2014
File:
PDF, 598 KB
english, 2014